ReviewMicroorganisms2021
Preventing Colorectal Cancer through Prebiotics.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study.Cancer immunology, immunotherapy : CII · 2024Trial
- Targeted Preparation of Low-Degree Polymerization Xylooligosaccharides From Lignocellulosic Biomass: Advances, Structure-Activity Relationships, and Applications.Journal of food science · 2026Review
- Fasting-mimicking diet counteracts gut microbial dysbiosis in experimental lynch syndrome.Cancer & metabolism · 2026Article
- Experimental models in immuno-oncology and their translational impact.Discover oncology · 2026Review
- Gut microbiota as a multifaceted modulator of prostate cancer: Mechanistic insights, therapeutic opportunities and clinical challenges (Review).Molecular medicine reports · 2026Review
- The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies.Discover oncology · 2026Review
- Helminth Infection, Gut Microbiome Alterations, and Their Impact on Pulmonary Tuberculosis Susceptibility.Journal of tropical medicine · 2026Review
- Circadian rhythms as a modulator of gut microbiota-tumor microenvironment crosstalk.Cellular and molecular life sciences : CMLS · 2025Review
- Dietary Supplementation of Compound Probiotics Improves Intestinal Health by Modulated Microbiota and Its SCFA Products as Alternatives to In-Feed Antibiotics.Probiotics and antimicrobial proteins · 2025Article
- In vitro effects of crocin on the possible anticancer properties of Lactococcus lactis against colorectal adenocarcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions.Biology · 2025Review
- Assessment of the relationship between gut microbiota, inflammatory markers, and colorectal cancer.Frontiers in cellular and infection microbiology · 2025Article
- Disturbance of the human gut microbiota in patients with Myotonic Dystrophy type 1.Computational and structural biotechnology journal · 2024Article
- An Update on Prebiotics and on Their Health Effects.Foods (Basel, Switzerland) · 2024Review
- Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy.Frontiers in immunology · 2024Review
- Prebiotics: Ignored player in the fight against cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer.Cancers · 2023Review
- Beneficial insights into postbiotics against colorectal cancer.Frontiers in nutrition · 2023Review
- Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy.Frontiers in immunology · 2023Review
- The effect of early colonized gut microbiota on the growth performance of suckling lambs.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer (CRC), the third most common cancer in the world, has been recently rising in emerging countries due to environmental and lifestyle factors. Many of these factors are brought up by industrialization, which includes lack of physical activity, poor diet, circadian rhythm disruption, and increase in alcohol consumption. They can increase the risk of CRC by changing the colonic environment and by altering gut microbiota composition, a state referred to as gut dysbiosis. Prebiotics, which are nutrients that can help maintain intestinal microbial homeostasis and mitigate dysbiosis, could be beneficial in preventing inflammation and CRC. These nutrients can hinder the effects of dysbiosis by encouraging the growth of beneficial bacteria involved in short-chain fatty acids (SCFA) production, anti-inflammatory immunity, maintenance of the intestinal epithelial barrier, pro-apoptotic mechanisms, and other cellular mechanisms. This review aims to summarize recent reports about the implication of prebiotics, and probable mechanisms, in the prevention and treatment of CRC. Various experimental studies, specifically in gut microbiome, have effectively demonstrated the protective effect of prebiotics in the progress of CRC. Hence, comprehensive knowledge is urgent to understand the clinical applications of prebiotics in the prevention or treatment of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.